E. I. du Pont de Nemours and Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From E. I. du Pont de Nemours and Company
With goal dates for almost 40 novel drugs and biologics coming up in the second half of 2020 after a record number of first half approvals, even the pandemic looks unlikely to prevent another solid year for innovative drugs at US FDA.
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
Emerging Company Profile: Based on its founders’ research at Yale, Azitra is developing topical therapies to treat skin dysbiosis associated with chemotherapy as well as two approaches to atopic dermatitis.
- Other Names / Subsidiaries